P1.01-80 ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients With EGFRm and NSCLC Treated With Osimertinib

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.636
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA10.05 an Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients With Uncommon EGFR Mutation(KCSG-Lu15-09)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-98 a Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients With Brain Metastases or Dose Reductions

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC With Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy